ONN® - OncLive News Network®


Evolving Adjuvant Treatments for HER2+ Early Breast Cancer

March 13th 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss clinical updates to the management of patients with HER2-positive early breast cancer.

Advances in the Management of Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma

February 23rd 2024

Nikhil I. Khushalani, MD, discusses the diagnosis, outcomes, treatment landscape, and future directions of locally advanced or metastatic cutaneous squamous cell carcinoma.

The Real-World Impact of CAR T-Cell Therapy in Large B-Cell Lymphoma

January 30th 2024

Experts explore the clinical significance and practical implications of recent findings regarding a CAR T-cell therapy in real-world settings.

BCMA-targeted CAR-T therapies in Relapsed/Refractory Multiple Myeloma

January 16th 2024

Two experts discuss the recent data presented at ASH 2023 on BCMA-targeted CAR-T therapies in relapsed/ refractory multiple myeloma patients.

End of Year Review in CRC: Exploring Emerging Treatment Options and Clinical Insights on the Future Landscape

December 19th 2023

Cathy Eng, M, FACP, FASCO presents a comprehensive End-of-Year Review in Colorectal Cancer (CRC), delving into the exploration of emerging treatment options and clinical insights on the future landscape. This insightful review includes a focus on the recent approval of fruquintinib and important updates on target therapies for HER2+, BRAF V600E-Mutant, and KRAS-mutant CRC, as well as an interactive Q&A segment.

ASH 2023 Study Highlights on the Real-World Impact of Liso-Cel in R/R Large B-Cell Lymphoma

December 14th 2023

Novel Agents Improving Outcomes for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm

December 14th 2023

Optimizing Outcomes in the Long-Term Management of Patients With AML

December 13th 2023

Catherine Lai, MD, MPH, discusses strategies for optimizing outcomes in the long-term management of Acute Myeloid Leukemia (AML), particularly for patients in first remission without a transplant. She also shares perspectives on updates from the 65th ASH Annual Meeting.

Evolving Treatment Strategies in Chronic Lymphocytic Leukemia: Insights From ASH 2023

December 13th 2023

Richard Furman, MD, and Chaitra S. Ujjani, MD, discuss the changing landscape of treatment strategies for patients with CLL, highlighting key updates presented at ASH 2023 and their potential implication on clinical practice.

Emerging Therapies in the Management of HR+, HER2- Metastatic Breast Cancer

December 13th 2023

Experts provides an in-depth review of current and emerging options for the treatment of HR+, HER2- metastatic breast cancer, including discussions around overcoming endocrine resistance, sequencing combination therapies, and optimizing quality of life and outcomes.

Optimizing Care Across the Continuum: Updates in the Detection and Treatment of Prostate Cancer

December 13th 2023

Expert oncologist discuss key data from 2023 on the detection and treatment of prostate cancer.

Advances in Hepatocellular Carcinoma (HCC): Key Updates from AASLD 2023 and Beyond

December 12th 2023

Anwaar Saeed, MD, and Amit Singal, MD, explore recent updates in the treatment of advanced hepatocellular carcinoma (HCC) presented at the 2023 AASLD: The Liver Meeting Congress and surrounding meetings.

Updates from IKCS 2023 and Surrounding Meetings in Advanced RCC

December 12th 2023

Brian Rini, MD, and Hans Hammers, MD, explore key data updates in the management of advanced renal cell carcinoma (RCC) presented at the 2023 IKCS: North America Congress and other recent meetings.

OncLive News Network: On Location at ASH 2023

December 11th 2023

Join us LIVE at this year's 2023 ASH Annual Meeting! OncLive® will broadcast a series of interviews with top thought leaders in hematologic malignancies, including chronic lymphocytic leukemia, acute lymphoblastic leukemia, myelodysplastic/myeloproliferative neoplasms, Hodgkin and non–Hodgkin lymphoma, multiple myeloma, and graft-vs-host-disease. The experts will share their insights and reactions to the pivotal data presented during the conference.

Post-Conference Perspectives Year in Review: 2023 Developments in Advanced or Recurrent Endometrial Cancer

November 20th 2023

Floor J. Backes, MD, and Matthew Powell, MD, explore key data updates in the management of advanced or recurrent endometrial cancer presented at the 2023 ESMO Congress and other recent meetings.

OncLive News Network: On Location at ESMO 2023

October 20th 2023

Join us LIVE at this year's 2023 ESMO Congress! OncLive® will broadcast a series of interviews with top thought leaders in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and gynecologic malignancies. The experts will share their insights and reactions to the pivotal data presented during the conference.

Expert Perspectives on Diagnosis, Management, and Emerging Therapies in Low-Grade Serous Ovarian Cancer

October 19th 2023

Expert perspectives on the current diagnostic and treatment landscape for patients with low-grade serous ovarian cancer and how recent learnings have impacted real-world practice.

The Effects of Real-World Evidence on the Treatment of HER2+ mBC

October 13th 2023

Joseph Gligorov, MD, reviews advancements in the treatment of HER2-positive breast cancer, including the pivotal DESTINY-Breast03 study, global perspectives, sequencing strategies based on French real-world evidence, and the management of adverse events in advanced therapies.

Evolving Treatment Strategies in High-Risk Neuroblastoma

August 31st 2023

Giselle Sholler, MD, and Anurag Agrawal, MD, discuss the changing landscape of treatment strategies for patients with high-risk neuroblastoma and review key clinical trial data presented at the ASCO 2023 Annual Meeting.

Post-Conference Perspectives: Managing R/R B-ALL with CAR T-Cell Therapy

August 22nd 2023

Jae Park, MD, reviews key data in the management of relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) recently presented at the ASCO 2023 Annual Meeting.